Intercure (INCR) vs MAIA Biotechnology (MAIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
MAIA Biotechnology (MAIA) has outperformed Intercure (INCR) over the past year, losing 29.1% versus a loss of 38.5%. Intercure is the larger company by market cap ($77.6 million vs $75.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCR | MAIA |
|---|---|---|
| Share price | $5.17 | $1.22 |
| Market cap | $77.57M | $75.33M |
| 1-day change | +2.99% | +6.09% |
| YTD return | +13.63% | -20.26% |
| 1-year return | -38.45% | -29.07% |
| 5-year return | -85.42% | — |
| Forward P/E | — | 1.10 |
| EPS (TTM) | $-0.98 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.32 | $3.19 |
| 52-week low | $3.40 | $0.87 |
| Distance from 52-week high | -37.86% | -61.76% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +883.61% |
| Average volume | 22.06K | 527.89K |
| Shares outstanding | 15.00M | 61.74M |
| Employees | 285 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Intercure
INCR stock →InterCure Ltd., together with its subsidiaries, engages in the production, manufacturing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil.
Health Care · Biotechnology: Pharmaceutical Preparations · 285 employees
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
INCR vs MAIA FAQ
Which is bigger, Intercure or MAIA Biotechnology?
Intercure (INCR) is larger, with a market capitalization of $77.57M compared with $75.33M for MAIA Biotechnology (MAIA).
Which stock has performed better over the past year, INCR or MAIA?
MAIA returned -29.07% over the past 12 months, compared with -38.45% for INCR (price return, excluding dividends). Past performance does not predict future results.
Are Intercure and MAIA Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.